Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MOGWAI
2022-500520-30-00Phase 3Authorised
- Sponsor
- Hospices Civils de Lyon
- Start
- Oct 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) comparing Azathioprine with Placebo (2 arms). Primary endpoint: Time to first relapse. Planned start Oct 2022; status: authorised.
02
Drugs
azathioprine
03
Conditions
myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD)
Beyond the preview
Go deeper on 2022-500520-30-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-500520-30-00.